Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 6/20 | 0.39 |
| ▸ | CES2 | O00748 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25125961 | 0.90 | TSHR (0.46) | ALDH1A1CES1CES2TSHRTDP1 | |
| SCHEMBL20976362 | 0.90 | TSHR (0.46) | ALDH1A1CES1CES2TSHRTDP1 | |
| SCHEMBL21901860 | 0.90 | TSHR (0.46) | ALDH1A1CES1CES2TSHRTDP1 | |
| SCHEMBL22592234 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TP53CES1CES2CA1 | |
| SCHEMBL4819387 | 0.78 | — | — | |
| SCHEMBL29169348 | 0.76 | ALDH1A1 (0.40) | ALDH1A1TP53CES1CES2CA1 | |
| SCHEMBL18312535 | 0.76 | FAAH (0.44) | ALDH1A1TP53CES1CES2FAAH | |
| SCHEMBL20716155 | 0.76 | CYP1A2 (0.36) | TSHRLMNATHRB | |
| SCHEMBL31347404 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TP53CES1CES2CA1 | |
| SCHEMBL11612267 | 0.74 | FDPS (0.41) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371420-A | Naphthyridones derivative and preparation method thereof | 上海翰森生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2021048469-A1 | POLYMER AND COMPOSITION FROM RENEWABLE SOURCE | ÅBO AKADEMI UNIVERSITY (FI) | 2021-03-18 | — | — | WO | disclosed |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190300477-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | ALDH1A1 3847/4885TP53 4276/4885CES1 3633/4885 |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1067/4885TP53 2529/4885CES1 2721/4885 |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | ALDH1A1 2851/4885TP53 722/4885CES1 3100/4885 |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | ALDH1A1 189/4885TP53 4517/4885CES1 353/4885 |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | KRAS, NRAS, G3BP2 | ALDH1A1 1492/4885TP53 15/4885CES1 4153/4885 |
| US-20190300477-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1067/4885TP53 2529/4885CES1 2721/4885 |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | AGBL2, LNPEP, DCLRE1B | ALDH1A1 3834/4885TP53 868/4885CES1 1303/4885 |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | ALDH1A1 3589/4885TP53 293/4885CES1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.